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Developing approaches to discover protein–protein interactions (PPIs) remains a fundamental challenge. A
chemical biology platform is applied here to identify novel PPIs for the AAA+ superfamily oncoprotein
reptin. An in silico screen coupled with chemical optimization provided Liddean, a nucleotide-mimetic
which modulates reptin's oligomerization status, protein-binding activity and global conformation.
Combinatorial peptide phage library screening of Liddean-bound reptin with next generation sequencing
identiﬁed interaction motifs including a novel reptin docking site on the p53 tumor suppressor protein.
Proximity ligation assays demonstrated that endogenous reptin forms a predominantly cytoplasmic
complex with its paralog pontin in cancer cells and Liddean promotes a shift of this complex to the
nucleus. An emerging view of PPIs in higher eukaryotes is that they occur through a striking diversity of
linear peptide motifs. The discovery of a compound that alters reptin's protein interaction landscape
potentially leads to novel avenues for therapeutic development.Introduction
Discovering protein–protein interactions (PPIs) remains a
major challenge.1 However, a detailed understanding of a pro-
tein's PPI network is central to novel biomedical applications.
Rate-limiting protein nodes need to be identied as they can
serve as a focus for novel diagnostic and/or therapeutic
advances. The current view is that drugging PPIs remains an
untapped landscape in the drug discovery eld.
The main approaches used to dene the PPIs of a target
protein include yeast two-hybrid methods2 and mass-spec-
trometry-based sequencing of multi-protein complexes using
tagged-bait proteins.3 Although powerful, their limitations are
that they are done outside an authentic cellular context, require
articial tagging of the bait protein and are unable to capture
weak, or dynamic interactions. One advance in the study of PPIs
is the idea that a large proportion of the polypeptide sequenceces Research Complex, University of St
ndrews, KY16 9ST, UK. E-mail: njw3@
of Edinburgh, EH9 3JG, UK. E-mail:
alling Unit, University of Edinburgh, EH4
ute, 656 53 Brno, Czech Republic
tion (ESI) available. See DOI:
hemistry 2015information in higher eukaryotes is intrinsically disordered
thus providing a template for “weak” regulatory, combinatorial
and specic PPIs to occur in signal transduction.4 A second
advance is the realization that a number of PPIs occur via a
linear amino acid motif1 that provides opportunities for
sequence based hotspots to be identied. Developing methods
to capture such consensus linear motifs of a target protein
would complement the technology currently used to discover
PPIs.
The AAA+ (ATPase associated with various cellular activities)
superfamily of proteins is present within all kingdoms of life.5
Members of this family exist as oligomers and form compelling
targets in understanding allosteric control of protein function.6
Reptin and pontin represent two highly conserved members
that are now viewed as model systems to dene fundamental
aspects of AAA+ superfamily function in eukaryotes.7 Reptin is
an important regulator of key cellular functions through a range
of PPIs.8–19 The diﬀerent oligomeric forms of reptin and its
ability to form a range of complexes with diﬀerent compositions
could underpin its functional diversity.20–22 The composition of
these oligomeric complexes must be tightly regulated and this
has been linked to reptin's bound ligand ATP/ADP.23,24 Devel-
opment of a synthetic ATP/ADP mimetic to probe the intrinsic
oligomerization properties of reptin and its ability to form
diverse PPIs could provide insight into the regulation and
function of reptin and the wider AAA+ family.Chem. Sci., 2015, 6, 3109–3116 | 3109
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View Article OnlineHere, a chemical biology platform is used to deliver a novel
tool to dissect the function of reptin. This approach involves; (i) in
silico screening of virtual libraries to identify novel ATPmimetics;
(ii) optimization of a hit as a PPI and oligomerization modier
giving the novel chemical tool, Liddean; (iii) use of combinatorial-
peptide libraries and next generation sequencing to identify novel
responsive PPIs; and (iv) cell based validation of ligand-activated
PPIs using proximity ligation assays. We also demonstrate thatFig. 1 Identiﬁcation of small molecules targeting reptin using an in silico
through a reptin–AGR2 peptide interaction assay of the top 30 hits from
analog obtained through chemical optimization (see Scheme S1 and Fig
shown as black sticks. The side chains of residues that comprise the act
colored white and shown as sticks. The pocket is also shown as a transpar
red, phosphorous orange, and chlorine green. See also Fig. S1 and S3.† (c
after pepsin proteolysis. Ligand free reptin protein (Fig. S7a†) was digeste
Processing of peptides was performed using HPLC-MS/MS with the instr
shown as green bars (1 minute) or black bars (ﬁve minutes) without or wi
fragment is highlighted. Shown are representative peptide fragments with
changes in deuterium exchange with ligand (–). The peptic peptides co
below the amino acid sequence. The sequence includes six residual N-ter
glutathione beads, amino acids and includes GPLGST (Fig. S7a and b†). (d
ADP molecule from reptin is shown as spheres in cyan. Regions with
increased deuterium exchange are shown in blue. Key regions which form
(arrow 2) & Y362-C375 (arrow 3)) are highlighted. The most dominant pe
Table S2†) map either around the ADP binding site or at the dimer interf
3110 | Chem. Sci., 2015, 6, 3109–3116our chemical tool Liddean (an ATP-mimetic) can be used to
discover and manipulate the PPIs of the AAA+ protein reptin.Results
In silico screening leading to a prioritized ATP mimetic
An in silico screen was used to identify small molecules that
might bind at the Walker A site on reptin. The rigid-bodyscreening programme. (a) Structure of hit compound 1 was identiﬁed
the in silico screen (see Fig. S1 and S2†) and Liddean, the most active
. S4 and S5†). (b) The Autodock prediction of the binding mode of 1 is
ive site are shown as green lines and are labeled. The ADP molecule is
ent surface representation. In all cases nitrogen is colored blue, oxygen
) Changes in hydrogen–deuterium exchange on reptin peptide motifs
d with pepsin after processing in the absence or presence of Liddean.
ument operated in a data-dependent mode. All identiﬁed peptides are
th Liddean (L) and the % change in deuteration as a function of peptide
increased or decreased deuterium exchange with ligand (*) or without
ver the majority of the sequence of reptin with the numbering shown
minal amino acids from the “tag” after precision protease cleavage from
) The reptin protein (PDB 3UK6) is displayed as a cartoon in green. The
suppressed deuterium exchange are shown in red and regions with
a dimer interface (R428-S439, arrow 1) and the ATP pocket (T81-G95
ptide fragments which show alterations in deuterium exchange ((c) and
ace.
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinedocking program LIDAEUS25 was used to dock a conformer
virtual library of 4.4 million compounds. The results were
ranked based on the LIDAEUS score and the top 49 971
compounds were redocked using Vina and Autodock (Fig. S1†).
A “rank-by-rank” consensus protocol prioritized hits, culmi-
nating in the selection of 30 compounds for assessment using
an ELISA assay17 with the peptide 104-FVLLNLVY-111 from the
known reptin binding protein AGR217 (Table S1†). Hits from this
assay were dened as compounds that modied (increased or
decreased) signicantly the signal corresponding to reptin
binding to the AGR2-peptide compared to control. Of the 30
compounds tested (Fig. S2†), compound 1 (Fig. 1a) led to the
most dramatic response and was therefore prioritized for study.
Compound 1 contains a biphenyl substituent that is predicted
to sit deep in the Walker A pocket where the adenine of ADP/
ATP binds and a pyridine–oxazolo ring system which is pre-
dicted to extend out of the pocket (Fig. 1b and S3†).Structure activity relationship and hydrogen–deuterium
exchange studies
The synthesis of 1 (Scheme S1†) provided suﬃcient material for
hit validation studies. An SAR study was then carried out to
improve the activity of 1. Modied analogs were either
purchased or synthesized (Schemes S1 and S2 and Fig. S4†). The
bromo-analog of 1, now called Liddean (Fig. 1a), was found to
be the most active analog. The results from this SAR study (see
Fig. S5† legend for a more detailed discussion), supported by
hydrogen–deuterium exchange (HDX) studies (Fig. 1c and d),26
were consistent with the proposed binding mode. Importantly,
suppression of HDX by Liddean was most pronounced forFig. 2 (a) The eﬀect of Liddean on the oligomerization dynamics of
reptin. (a) Reptin (1 mg) was subjected to denaturing SDS (0.1%) gel
electrophoresis in ADP binding buﬀer without or with ADP (100 mM) or
Liddean (100 mM), as indicated. After 30 minutes of incubation at room
temperature, gel loading buﬀer was added (with 1% SDS concentra-
tion), and electrophoresis was then carried out. Reptin protein was
visualized by silver staining. See Fig. S8† for additional data. (b) The
eﬀect of Liddean on the interaction of reptin with the molecular
chaperone HSP90. SBP-tagged HSP90 was captured on streptavidin
coated wells and reptin (100 ng) was added in the ligand free and
ligand bound states (100 mM where indicated). After washing the
amount of reptin bound was quantiﬁed using an anti-reptin polyclonal
antibody and peroxidase conjugated-anti rabbit IgG. The data are
plotted as relative reptin activity (in RLU) as a function of the ligand
bound state of reptin. CON ¼ control.
This journal is © The Royal Society of Chemistry 2015amino acids 362–375 in the Walker A site (Fig. S6†). Interest-
ingly, an increased rate of HDX was observed along the length of
the a-helix (81–95) that contacts to the Walker A site. In addi-
tion, deuterium exchange was suppressed for amino acids 428–
439 which are located at the known protein–protein interface in
reptin homodimers (Fig. 1c and d). It was therefore decided to
assess whether Liddean had an eﬀect on the oligomerization
status of reptin.
Liddean alters reptin's oligomerization status
Oligomerization of reptin is known to increase in the presence
of bound ligands ATP or ADP.24 Reptin was subjected to SDS
denaturing (0.1%) electrophoresis in the presence of varying
amounts of SDS (Fig. 2a and S8a†). The preincubation of reptin
with Liddean induced the formation of a stable oligomeric form
of reptin (MWz 250 kDa, Fig. 2a) as well as additional bands,
corresponding to higher order oligomers (possibly hexamers
based on the apparent mass). These data suggested thatFig. 3 Discovery of new Liddean-dependent interaction motifs for
reptin. Next generation sequencing of peptide-phage pool obtained
from a reptin screen in the apo and ligand bound state. Reptin was
captured onto the solid phase without or with ligands ADP or Liddean.
After selection of the peptide library on reptin protein, elution and
propagation in bacteria, the phage DNA was ampliﬁed using PCR
primer sets that capture the sequences ﬂanking the peptide insert (as
in Fig. S9†). Pooling of all phage into deep sequencing reactions can be
done with subsequent deconvolution using the “bar code” whose
position in the primer is indicated. (a) Parameters from the sequencing
reactions from a representative screen are summarized. These
include: (i) the sequencing reads before ﬁltering non-speciﬁc binding
peptides; (ii) the number of sequencing reads in apo or ligand bound
protein; (iii) and the number of peptides that are shared in a number of
apo or ligand bound screens. (b and c) Representative peptides that are
enriched in the ligand bound state or suppressed in the ligand bound
state are indicated to highlight a representative set of raw sequencing
reads. (d) An example ciliopathy protein present in the list of human
proteins which contain consensus sites identiﬁed by our Liddean-
bound reptin screen. Processing the top 500 peptides from the apo
and Liddean bound reptin usingMEME to identify the top 10 consensus
motifs (http://meme.nbcr.net/meme/cgi-bin/meme.cgi) highlights
the distinct sets of motifs acquired in the apo and ligand bound form.
The motifs were processed using MAST or blastp to identify targets in
the human proteome that have matches to these motifs, some of
which are listed as potential ciliopathy targets.
Chem. Sci., 2015, 6, 3109–3116 | 3111
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View Article OnlineLiddean was able to modify reptin's oligomerization dynamics
with reptin being present in a more stable oligomeric state in
the presence of Liddean. Liddean was also more eﬀective at
stabilizing reptin than ADP (Fig. 2a) with as little as 2 mM Lid-
dean inducing stable oligomers (Fig. S8b,† lane 2). An attempt
to correlate Liddean's ability to induce reptin homo-oligomeri-
zation and its stimulation of reptin's binding to the AGR2
peptide proved successful (Fig. S8†).
The link between nucleotide-induced changes in oligomer-
ization status and function is a key feature of AAA+ proteins
including reptin. To assess whether our Liddean-induced
change in oligomerization status led to a modication of rep-
tin's PPIs, we initially evaluated the eﬀect of Liddean on rep-
tin's known PPI with the molecular chaperone HSP90.
Streptavidin-mimetic tagged (SBP) HSP90 was captured on
solid phase followed by the addition of either apo-, ADP- or
Liddean-bound reptin. Liddean (and to a lesser extent ADP)
increased the stability of the reptin–HSP90 complex (Fig. 2b).
Encouraged by the fact that clear changes could be observed in
the presence of Liddean, we next used it as a tool to examine
Liddean-induced changes on the global peptide-binding space
of reptin.Fig. 4 Identiﬁcation and validation of p53 as a novel reptin interacting
protein. (a) 1000 peptides that were enriched in the ligand bound state
(including those shown) were processed using MEME to identify
consensus motifs (http://meme.nbcr.net/meme/cgi-bin/meme.cgi).
(b) The panel represents data from a 12-mer peptide screen where the
core motif identiﬁed is highlighted as fRERf or LRER[L/G]. (c) A blast
motif screen using theMEME derived peptide consensus sites gave rise
to a peptide derived from the tumor suppressor protein p53. (d)
GST-tagged reptin and AGR2 proteins were assayed for their ability to
bind to full length p53 using ELISA. p53 protein was absorbed onto the
solid phase, and the indicated proteins were titrated in solution phase.
The binding was detected using GST antibodies, followed by peroxi-
dase conjugated secondary antibodies and processing using chem-
iluminescence. The data is plotted as binding activity as a function of
protein amount (in RLU). (e) The eﬀect of Liddean on the stability of the
reptin–AGR2 and reptin–p53 protein interactions was evaluated.
Either p53 or AGR2 were absorbed onto the solid phase and reptin
(200 ng) was added in 50 ml of buﬀer containing increasing amounts of
the indicated ligand. After 60minutes incubation at room temperature,
reptin protein bound to its target was quantiﬁed as indicated in the
methods (in RLU).
3112 | Chem. Sci., 2015, 6, 3109–3116Discovering new Liddean-stimulated peptide docking motifs
on reptin using next generation sequencing of a phage-
peptide combinatorial library
A combinatorial peptide-based selection assay exploiting next-
generation “deep” DNA sequencing of peptide-phage pools was
carried out using reptin in its ligand-free, ADP- or Liddean-
bound form. Peptides were processed through 3 rounds of
biopanning using a 12-mer peptide library, and peptide pools
were sequenced (Fig. 3a, S9 and Table S3†). Comparison of the
peptides identied using apo-reptin with those obtained when
Liddean-bound reptin was used showed that, as expected, the
binding of some peptides to reptin were suppressed (for
representative raw peptide reads see Fig. 3b) or elevated by
Liddean (Fig. 3c). Recent data has shown that reptin has an
important interaction with the cytosolic cilia machinery.27,28
This is a new cellular interactome for reptin distinct from its
known links to the chaperone and transcription systems. It is
interesting to note that several ciliopathy proteins are present inFig. 5 Fine mapping of the dominant linear peptide docking site of
reptin on p53. (a) The domain structure of p53 including the sites
bound by MDM2 (in green), proline rich motif (blue), the speciﬁc
DNA-binding domain (pink); tetramerization domain (yellow); and the
C-terminal regulatory domain (in red). The arrows highlight the two
binding sites mapped for reptin (in panels below). (b) An overlapping
series of synthetic biotinylated peptides derived from the open reading
frame of p53 were captured on streptavidin coated solid phase and
reptin binding wasmeasured as indicated in themethods. Two domain
regions from p53 bound to reptin and mapped to the BOX-V domain
(RNS.GRD) and to the tetramerization domain (YFT.EMF). The latter
peptide contain two repeats of the fRERf or LRER[L/G] motifs iden-
tiﬁed from the ligand responsive peptides using MEME (Fig. 4). (c)
Alanine scan mutagenesis of peptide 38 identiﬁes important amino
acids for reptin binding to p53; in the core sequence IRGRERFEMF,
mutating IRGR or the overlapping RERF motif abrogates reptin binding
to p53. This functional alanine mutagenesis is consistent with the
MEME derived peptide motif from the deep sequencing.
This journal is © The Royal Society of Chemistry 2015
Fig. 6 The eﬀects of Liddean on reptin–pontin interactions in cell
models using the proximity ligation assay. HCT116 cells were pro-
cessed using the proximity ligation method to identify whether reptin
forms a PPI in cells and the images are superimposed using DAPI to
highlight the nuclear (blue) or cytosolic foci location. The data high-
light the foci of: (a) reptin–pontin in DMSO treated cells; (b) reptin–
pontin foci in cells treated with 2 mM Liddean. (c) Number of cytoplasm
(black bar) and nuclear (white bar) foci in the absence of presence of
Liddean (1 mM and 2 mM). See Fig. S11† for the image of HCT116 cells in
the presence of 1 mM Liddean; (d) immunoblots that show the amount
of reptin or pontin after chemical fractionation into cytoplasmic,
mitochondrial, and nuclear fractions.
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View Article Onlinethe list of human proteins which contain consensus sites
identied by our Liddean-bound reptin screen (Fig. 3d for one
example, and Fig. S10†). Whilst the identied binding sites have
yet to be validated, these data are entirely consistent with this
approach being able to deliver a molecular peptide-binding
“ngerprint” for reptin. In addition, the change in binding
motifs identied in the presence of Liddean, linked with this
ligand's observed eﬀect on the oligomerization of reptin,
provides indirect evidence for a substantial allosteric eﬀect on
the peptide-binding prole of reptin.
During these studies, several consensus peptide motifs were
identied that were enriched in both ADP and Liddean bound
forms. Our attention was drawn to the enrichment of motifs
containing a fRERf sequence by ADP and/or Liddean (Fig. 4a
and b). When this motif was compared with the human pro-
teome, a motif was identied in the tetramerization domain of
the p53 tumor suppressor (Fig. 4c). An ELISA assay demon-
strated that the reptin protein was able to bind to puried
human p53 whereas GST and AGR2 did not (Fig. 4d). Liddean
was shown to stabilize the p53–reptin complex, consistent with
the results from peptide-phage display (Fig. 4e).
In order to ne map the reptin binding site on p53, over-
lapping biotinylated peptides from human p53 (Fig. 5a and b)
were probed with reptin to evaluate binding. Two dominant
peptides (Fig. 5b), one which overlapped with the knownMDM2
binding site in the central domain of p53 (peptide 31) and one
with a motif in the tetramerization domain of p53 (peptide 38)
bound to reptin. This provides at least two docking sites
for reptin on p53. Alanine scanning mutagenesis of peptideThis journal is © The Royal Society of Chemistry 201538 revealed that the key amino acid contacts required for eﬃ-
cient reptin binding to p53 form the core fRERfmotif (Fig. 5c).
These data further conrmed that our peptide combinatorial
screen linked with next-generation sequencing can identify
dominant docking sites for reptin on substrates and that Lid-
dean can induce changes in reptin binding activity to important
proteins such as AGR2, HSP90, ciliary proteins and p53.Evaluation of the eﬀects of Liddean on reptin–pontin
interactions in a cell-based assay
In the nal part of this study we assessed whether Liddean
could be used to study reptin function in cells. To do this rep-
tin's interaction with its most dominant paralog, pontin was
observed using proximity ligation assays29 in HCT116 cells. The
complex between reptin and pontin was found to be largely
cytoplasmic in the absence of Liddean (Fig. 6a; DMSO only). By
contrast, Liddean (used at up to 2 mM) led to a substantial
reduction in the cytoplasmic reptin–pontin foci and a change
from clear punctate nuclear foci to aggregated reptin–pontin
foci (Fig. 6b, c and S11†). Similar results were observed in p53-
null cells (Fig. S12a–c†). Reptin and pontin expression levels
were found to be equivalent with or without Liddean with the
majority of both proteins being in the cytoplasmic fractions,
relative to the mitochondrial and nuclear fractions using
chemical fractionation (Fig. 6d). However, since the nucleus can
be leaky in such chemical fractionation experiments, we also
evaluated reptin and pontin proteins using immunouores-
cence (IF; Fig. S12d–g†). The total amounts of reptin or pontin
proteins also remained relatively unchanged in the absence or
presence of Liddean (Fig. S12d–g†) and as dened by immu-
noblotting using urea lysis buﬀer (Fig. S12h and i†). Although
the IF demonstrates a largely cytosolic reptin pool (Fig. S12d
and f†), pontin does indeed show mixed cytosolic and nuclear
pools (Fig. S12e and g†) suggesting the chemical fractionation
does induce a leaching of pontin into the cytosol. These data
together indicate that Liddean does not induce global changes
in reptin or pontin protein levels or localization, but instead
stimulates the production of reptin–pontin complexes in the
nucleus. Together with the previous experiments, these data
validate Liddean as a novel chemical tool with which to probe
both in vitro and in vivo changes in the functions of the AAA+
protein reptin.Discussion
The AAA+ proteins, including reptin, are known for their
nucleotide binding sites, oligomeric propensity, and wide range
of functions.5 Here we built on the observation that nucleotide
binding is known to regulate the oligomerization status of
reptin. In particular, we were interested in exploring whether by
modifying reptin's oligomeric state we would change the
proteins it interacts with.30 A number of assays could have been
used to screen for novel reptin ligands, including helicase
activity, ATPase activity, fragment based drug discovery, and/or
high throughput competitive binding with nucleotide ligands.31
Indeed, a recent approach has identied small moleculeChem. Sci., 2015, 6, 3109–3116 | 3113
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View Article Onlineinhibitors of the ATPase activity of the reptin paralog, pontin.32
Instead we used an in silico screen to predict small molecules
that would target the deep nucleotide binding pocket (Walker A
site) that is a characteristic feature of oligomeric AAA+ proteins.
The identied hit (compound 1) was subjected to SAR analysis
guided by an ELISA based PPI assay to generate the chemical
tool, Liddean. The SAR data and results from hydrogen–deute-
rium (H–D) exchange experiments supported our proposal that
Liddean binds in the Walker A site of reptin. In addition, Lid-
dean stabilised higher order oligomers of reptin as evidenced by
(i) the estimated mass using a denaturing gel electrophoretic
screen and (ii) the use of HDX experiments that revealed
suppression of deuterium incorporation at the previously
reported dimer interface.
Reptin is known to interact with a variety of chromatin and
chaperonin signalling proteins and is oen considered impor-
tant in oncogenesis.33 More recently, based on genetic screens,
reptin has been linked to the assembly of cilia structures on the
plasma membrane.27,28 With Liddean in hand, we decided to
assess whether it could be used to nd and provide details
about reptin PPIs. As a proof of principle we conrmed that
Liddean-bound reptin modied reptin's known interaction with
HSP90. Next we decided to use the stabilized, oligomeric state of
Liddean-bound reptin in vitro to search for “consensus peptide
motifs” using a combination of next generation deep-
sequencing and a combinatorial peptide-phage library. Whilst a
very information rich dataset was obtained, our focus turned to
a novel reptin-interacting motif in the p53 tumor suppressor
protein. Independent screens veried that indeed reptin can
bind to p53-derived peptides mainly through a peptide motif
that is located in the p53 tetramerization domain (Fig. 4 and 5).
As a further demonstration of the utility of our approach, it was
also noted that peptide motifs in proteins of the cytosolic cilia
machinery were identied. On-going studies will probe the
details of these proposed interactions.
Whilst Liddean had proved a very useful tool in vitro, we
wanted to assess whether it could also be used in cells. A
proximity ligation assays29 was therefore used to assess the
eﬀect of Liddean on the interaction of reptin with its dominant
partner, pontin, in cells. This technique enabled us to observe
directly the reptin–pontin complex in the cytoplasm of cancer
cells. Interestingly, reptin formed signicantly more nuclear
foci with pontin on addition of Liddean. Whilst an explanation
for this observed redistribution remains challenging, dramatic
changes in protein expression levels or localization have been
ruled out.
Conclusions
In discovering and subsequently using Liddean, our chemical
biology platform has provided novel insights into the PPIs
associated with the important human protein reptin. Ulti-
mately, identifying reptin's complete PPI network and explain-
ing how the network is controlled is central to understanding its
role in normal and disease processes. An important concept
relating to PPIs is that small linear peptide motifs can form
dynamic and specic docking sites for a protein.34–36 Small3114 | Chem. Sci., 2015, 6, 3109–3116molecule stabilization/destabilization of thesemotifs provides a
promising approach towards overall modulation of protein
function.1 Indeed, there are PPI drug leads emerging that are
being applied in the clinic; the most notable of which targets
the linear peptide motif-binding groove of the MDM2 onco-
protein.37 As dynamic linear peptide-motif based PPIs form a
vast untapped landscape in biology and medicine,38 approaches
that facilitate the discovery of such interactions will provide new
avenues to impact on drug discovery programs.39 We believe
that the approach we have outlined in this report is applicable
to other members of the AAA+ superfamily.Materials and methods
Protein–protein interaction assays of reptin
The expression and purication of reptin protein was carried
out as previously described17 and as discussed in Fig. S13† with
the following exceptions. The cells were initially put into a
buﬀer containing 50 mMHEPES pH 8.0 and 10% sucrose before
being snap frozen, the rest of the components of the lysis buﬀer
were then added with the exception of Triton X-100 which was
added at a 0.1% concentration rather than 0.5%. The lysate was
incubated with glutathione beads for 150 minutes at 4 C with
rotation before the washes were carried out. The protease used
to cleave the reptin from the beads was HRV 3C. Biotinylated
AGR2 derived peptides (or p53 where indicated) were coated
overnight onto streptavidin coated wells and reptin binding was
measured in buﬀers as described previously.17 All biotinylated
peptides were obtained from Chiron Mimotopes (Australia).
When small molecules were evaluated to the indicated nal
concentrations (balanced with DMSO carrier), reptin was added
immediately to the reaction well to allow binding competition
to take place in the presence of the AGR2 (or p53) peptide. The
wells were washed17 and bound reptin was detected using a
reptin antibody coupled to anti-rabbit secondary antibody and
chemiluminescence. Binding activity was quantied by chem-
iluminescence using a Fluoroskan Ascent FL Labsystems. For
measuring the eﬀects of ligands on the SDS-resistant oligo-
merization state of reptin using SDS gel electrophoresis, reptin
protein (1 mg) was added to buﬀer B (25 mM HEPES, pH 8.0;
10% glycerol, 10 mM KCl, 1 mM DTT) with the indicated
amounts of ADP or Liddean. Following incubation at room
temperature for 60 minutes, samples were processed for elec-
trophoresis as indicated in the Fig. S8† legend.Hydrogen–deuterium exchange mass spectrometry
Deuteration of the reptin either free or in complex with Liddean
was initiated by a sequential dilution into deuterated water with
0.1% DMSO nal concentration. The molar ratio between reptin
and Liddean was 1 : 5 (as summarised in Fig. S7†). The
exchange was done at 21 C and was quenched by the addition
of 1 M HCl in 1 M glycine at 1 min and 5 minutes followed by
rapid freezing in liquid nitrogen. Each sample was quickly
thawed and injected onto an immobilized pepsin column (15 ml
bed volume, ow rate 20 ml min1, 0.1% formic acid in water).
Peptides were trapped and desalted on-line on a peptideThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinemicrotrap (Michrom Bioresources, Auburn, CA) for 1 minute at
a ow rate 20 ml min1. The peptides were eluted onto an
analytical column (Jupiter C18, 1.0  50 mm, 5 mm, 300 A˚,
Phenomenex, CA) and separated by a linear gradient. The
injection, switching valves, immobilized pepsin column, trap
cartridge, and the analytical column was kept at 1 C in a cool
box (within the robotics system). Mass spectrometric analysis
was done on an Orbitrap Elite mass spectrometer (Thermo
Fisher Scientic) with ESI ionization on line connected with a
robotic system based on a HTS-XT platform (CTC Analytics
company). The instrument was operated in a data-dependent
mode for peptide mapping (HPLC-MS/MS). Each MS scan was
followed by MS/MS scans of the top three most intensive ions
from both CID and HCD fragmentation spectra. Tandem mass
spectra were searched using SequestHT against the cRap
protein database (p://p.thegpm.org/fasta/cRAP) containing
sequence of reptin protein. Sequence coverage was visualized
with Proteome Discoverer 1.4 soware (Thermo Fisher Scien-
tic). Analysis of deuterated samples was done in HPLC-MS
mode with ion detection in the orbital ion trap and data were
processed in HDX Workbench. Graphs showing deuteration
kinetics were plotted by DrawHDXPlot (MSTools).Combinatorial peptide phage screen
Peptide phage was carried out using the 12-mer Ph.D.™ Phage
display library (New England Biolabs). The surface panning
procedure (direct target coating) was carried out as instructed
by the manufacturer's protocol with an additional protein
capture step. Themicro titer wells were coated as directed with a
rabbit anti-reptin polyclonal antibody overnight. The wells were
then washed three times with tris buﬀered saline with 0.1%
Tween-20 (TBST). The wells were then blocked with 3% bovine
serum albumin in TBS for 1 hour. Washes were once again
carried out before the addition of reptin with and without
ligand (either ADP or Liddean at 100 mM) and incubated for one
hour at RT. Washes were then carried out 6 times with TBST,
containing ligand in the ligand treated wells. The phage pool
was then added, again containing ligand if required, and
incubated for 1 hour. Non-binding phage was removed and the
wells were washed 10 times with PBST prior to the elution of the
phage as directed by the manufacturer. Amplication and
titering of the phage was also carried out with each round of
panning as per the manufacturer's instructions. Titering was
carried out to ensure that the phage pool being panned was not
greater than that of the original pool once it had been amplied
and to check for white-type lytic phage contamination. Poly-
merase chain reaction (PCR) and deep sequencing of phage was
carried out in the following stages; (i) PCR was used to amplify
phage DNA from each round of screening using the primer bar
codes in table code (Table S3†) that have an Illumina adaptor
sequence and a 3 letter bar code; (ii) equal amounts of DNA was
gel puried on a 2% agarose gel to create a pool (5 mg) that was
sequenced by Otogenetics (USA). Fastq les were then captured
using a custom tool programmed in Java language (script
available upon request) that was used to extract amino acid
sequences from raw NGS reads. Only forward reads wereThis journal is © The Royal Society of Chemistry 2015processed (as reverse reads do not capture the bar code). Bar-
code and mimotope DNA sequences were extracted from reads
that passed quality control based on exact match search for
bordering sequences. All sequences having nonsense (not in
list) bar code were ltered out. Mimotope sequences having
inappropriate length or containing nonsense codons (stop
codons as well as some other “forbidden” codons that should
not be present according to New England BioLabs phage library
manual) were ltered out. Sequences passing these lters were
translated, grouped by resulting peptide sequence and sorted as
indicated in the tables.Duo-link proximity ligation assay
Cells were grown on coverslips until they reached around 30%
conuency upon which the small molecule Liddean was trans-
fected into cell and incubated for 24 hours (transfection was
performed using 1 or 2 mM molecule with DMSO control
balanced in 100 ml of DMEM containing attractene carrier).
Cells were xed with 4% paraformaldehyde dissolved in PBS
and permeabilized using 0.25% Triton X-100 in PBS. Duolink II
(green) assay from Olink Bioscience was carried out following
manufactures instructions. Briey, unspecic antibody binding
was blocked by the addition of 3% BSA (w/v) in PBS for
30 minutes at room temperature. Primary antibodies were
diluted in 3% BSA (w/v) in PBS and added to the cells overnight
at 4 C. Negative controls include no primary or no secondary
antibodies which gave rise to no foci in subsequent assay pro-
cessing (data not shown). PLA probes were added to cells and
incubated to 1 hour at 37 C. Ligation mix was added for
30 minute at 37 C followed by the polymerase amplication
mix for 2 hours at 37 C. Coverslips were mounted in S3023
Mounting medium (Dako). Results were visualized using a BX51
(Olympus) uorescent microscope. Antibodies and PLA probes
include; anti-reptin/TIP49B/RUVB2 rabbit antibody ab36569
(abcam) (1 : 250 dilution); monoclonal anti-pontin 5G3-11
(Sigma) (1 : 250 dilution); Duolink II PLA probe anti rabbit PLUS
(Olink) (1 : 10 dilution); and Duolink II PLA probe anti mouse
MINUS (Olink) (1 : 10 dilution).Acknowledgements
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